Other approaches that are in development include fibroblast growth factor (FGF) mimetics such as FGF21-targeting candidates ...

Nearly all MASH drugs in development either focus on direct liver defatting from lipolysis or indirect liver defatting from weight loss, not both. The only exceptions are Survodutide, Retatrutide ...

Retatrutide, Lilly's triple agonist ... might allow Zealand/Boehringer to reach regulatory approval in obesity & MASH, pending positive clinical trials performance, before Altimmune's Pemvidutide ...

Retatrutide is a once-weekly injection from pharmaceutical company Eli Lilly, which is in the process of completing phase 2 trials to study the drug for both weight loss and managing type 2 diabetes.